What is the initial workup for thrombocytosis?

Initial Workup for Thrombocytosis

Begin by confirming persistent thrombocytosis (platelet count ≥450 × 10³/μL) with a repeat complete blood count (CBC) with differential and peripheral blood smear, then systematically evaluate for secondary causes before pursuing molecular testing for myeloproliferative neoplasms. 1

Step 1: Confirm and Characterize the Thrombocytosis

• Repeat CBC with differential to confirm persistent elevation (not a transient or spurious finding)
• Peripheral blood smear to assess platelet morphology and evaluate other cell lines for dysplasia or left-shift suggesting myeloproliferative neoplasm 1
• Document the degree: mild (450-700), moderate (700-900), severe (900-1,000), or extreme (>1,000 × 10³/μL)

Step 2: Clinical Assessment for Secondary Causes

Most thrombocytosis is secondary and will resolve with treatment of the underlying condition 1. Actively look for:

High-Yield Clinical Factors Suggesting Secondary Thrombocytosis:

• Active malignancy (strongly associated with secondary causes) 2
• Chronic inflammatory disease (rheumatologic conditions, inflammatory bowel disease) 2
• Recent or remote splenectomy 2
• Iron deficiency anemia (check even if hemoglobin is normal) 2
• Active infection or recent infection 1
• Recent surgery, trauma, or bleeding
• Medications (all-trans retinoic acid, growth factors)

Clinical Factors Suggesting Primary Thrombocytosis (Essential Thrombocythemia):

• History of arterial thrombosis (predictive of ET) 2
• Microvascular symptoms: erythromelalgia, headaches, paresthesias 1
• Splenomegaly on examination 1
• Unexplained bleeding or thrombosis 1

Step 3: Initial Laboratory Testing

Order the following tests based on clinical assessment:

Essential Initial Labs:

• C-reactive protein (CRP) - elevated suggests reactive/secondary thrombocytosis 1
• Ferritin and complete iron studies - iron deficiency is a common secondary cause and must be excluded even with normal hemoglobin 3, 2
• Review other CBC parameters:
  • Higher hemoglobin, MCV, RDW, and MPV suggest ET 2
  • Higher WBC and neutrophils suggest secondary thrombocytosis 2

Additional Considerations:

• If inflammatory markers elevated: pursue underlying inflammatory/infectious cause
• If iron deficiency present: trial of iron replacement therapy is required to exclude occult polycythemia vera 3

Step 4: Molecular Testing (If Secondary Causes Excluded)

Only proceed to molecular testing if thrombocytosis persists without an identified secondary cause 2. The diagnostic yield is approximately 52%, with 92% being JAK2, CALR, or MPL mutations 2.

Sequential Molecular Testing Approach:

1. JAK2 V617F mutation (first-line test) 3, 1
2. If JAK2 negative: Test for CALR and MPL mutations 1
3. Consider broader next-generation sequencing panel only if clinical suspicion remains high

Common pitfall: Ordering expensive molecular panels prematurely before excluding secondary causes wastes resources and may yield incidental findings of uncertain significance 2.

Step 5: Bone Marrow Biopsy

Bone marrow biopsy is required for definitive diagnosis of essential thrombocythemia, even in JAK2-positive patients 3. This is necessary to:

• Differentiate ET from other myeloproliferative neoplasms (especially prefibrotic myelofibrosis)
• Exclude myelodysplastic syndromes
• Confirm megakaryocytic proliferation with mature, enlarged megakaryocytes
• Assess for reticulin fibrosis
• Rule out JAK2-negative ET versus reactive thrombocytosis 3

WHO Diagnostic Criteria for ET (All 4 Required):

1. Sustained platelet count ≥450 × 10³/μL 3
2. Bone marrow showing megakaryocytic proliferation with enlarged, mature megakaryocytes 3
3. Not meeting criteria for PV, PMF, CML, MDS, or other myeloid neoplasm 3
4. Presence of JAK2 V617F or other clonal marker, OR absence of evidence for reactive thrombocytosis 3

Key Caveats

• The threshold was lowered from 600 to 450 × 10³/μL because the 95th percentile for normal platelet count is below 400 × 10³/μL, and the higher threshold compromised detection of early-phase disease 3
• A patient may have ET with a concomitant reactive condition; diagnosis can still be made if the first 3 WHO criteria are met 3
• JAK2 mutation has limited utility for ET diagnosis due to suboptimal negative predictive value (only 50% of ET patients are JAK2-positive) and lack of specificity within myeloid neoplasms 3
• In iron-deficient patients, exclude occult polycythemia vera by trial of iron replacement before diagnosing ET 3